ANDA 205331, held by Eugia Pharma. Adenosine.
As of Nov 13, 2026, ANDA 205331 (Adenosine), held by Eugia Pharma, was first approved by FDA on Nov 2, 2017, with 0 approved supplements and 0 published complete response letters.
Adenosine injection, USP is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 2, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
